- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.09. | NKGen Biotech, Inc.: NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum | 1 | GlobeNewswire (USA) | ||
| 10.09. | NKGen Biotech, Inc.: NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 | 3 | GlobeNewswire (USA) | ||
| 17.07. | NKGen Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.07. | NKGen Biotech, Inc.: NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions | 1 | GlobeNewswire (USA) | ||
| 02.06. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| NKGEN BIOTECH Aktie jetzt für 0€ handeln | |||||
| 21.05. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | NKGen Biotech, Inc.: NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment | 249 | GlobeNewswire (Europe) | New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer's disease. SANTA ANA, Calif.... ► Artikel lesen | |
| 04.05. | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | NKGen Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.03. | NKGen Biotech, Inc.: NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026 | 241 | GlobeNewswire (Europe) | Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to... ► Artikel lesen | |
| 22.01. | NKGen Biotech, Inc.: NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board | 307 | GlobeNewswire (Europe) | SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 106,83 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| PRAXIS PRECISION MEDICINES | 239,15 | +0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,510 | 0,00 % | Harmony Biosciences Holdings, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 23,650 | -0,08 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| MBX BIOSCIENCES | 48,820 | 0,00 % | Stifel raises MBX Biosciences price target to $84 on obesity drug data | ||
| ALAUNOS THERAPEUTICS | 2,070 | 0,00 % | Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,125 | -0,03 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| ERASCA | 14,695 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 21,840 | -0,18 % | Structure Therapeutics auf Morgan-Stanley-Konferenz: Orale Pipeline gewinnt an Dynamik | ||
| RECURSION PHARMACEUTICALS | 3,735 | -0,13 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| TANGO THERAPEUTICS | 22,195 | 0,00 % | JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data | ||
| PROTAGONIST THERAPEUTICS | 136,29 | +0,01 % | Protagonist Therapeutics Announces $300 Million Share Repurchase Program | NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the... ► Artikel lesen | |
| TREVI THERAPEUTICS | 12,060 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting | ||
| ARCUTIS BIOTHERAPEUTICS | 26,430 | +0,08 % | Arcutis präsentiert Studiendaten zur ZORYVE-Creme bei Säuglingsekzemen | ||
| COGENT BIOSCIENCES | 28,140 | -0,04 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen |
NKGEN BIOTECH INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NKGEN BIOTECH INC finden Sie auf Wallstreet Online.